DOCSLIB.ORG

Factor Analysis on Cannabis

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Factor Analysis on Cannabis SCHEDULING CANNABIS: A PREPARATORY DOCUMENT FOR FDA’S 8-FACTOR ANALYSIS ON CANNABIS A SCIENTIFIC APPROACH FOR CONGRESS, DRUG ENFORCEMENT ADMINISTRATION, AND DEPARTMENT OF JUSTICE Prepared by Americans for Safe Access (2016) Reviewed by Jahan Marcu, Ph.D., Ethan Russo MD, Lumir Hanus, Ph.D., Roger Pertwee, Ph.D., Steph Sherer, and Jason Schechter, Ph.D. ASA | Scheduling Cannabis: A PreparaTory DocumenT for FDA’s 8-FacTor Analysis on Cannabis The research and analysis in this report was conducted by Americans for Safe Access Foundation, a 501(c)(3) non-profit organization. Publication date July 2016 With over 100,000 active members in all 50 states, Americans for Safe Access (ASA) is the largest national member-based organization of patients, medical professionals, scientists and concerned citizens promoting safe and legal access to cannabis for therapeutic use and research. ASA works to overcome political and legal barriers by creating policies that improve access to medical cannabis for patients and researchers through legislation, education, litigation, grassroots actions, advocacy and services for patients and their caregivers, the medical cannabis industry, and governments. Copyright © 2016 Americans for Safe Access Foundation™ All rights reserved. No part of this publication may be reproduced in any form by any electronic or mechanical means without permission in writing from Americans for Safe Access. Learn more about ASA at AmericansForSafeAccess.org. 1624 U Street NW, Suite 200, Washington, D.C. 20009 Phone: 1-888-929-4367 fax: 202.857.4273 2 | Americans for Safe Access A Scientific Approach for Congress, Drug Enforcement Administration, and Department of Justice TABLE OF CONTENTS I. InTroducTion .......................................................................................................................................................... 5 II. Background ......................................................................................................................................................... 6 III. EvaluaTing Cannabis Under The 8 FacTors ................................................................................................ 9 Factor 1: Cannabis’ Actual or Relative Potential for Abuse ............................................................................................. 9 a. Individuals are not taking the substance in amounts sufficient to create a hazard to their health or to the safety of other individuals or to the community. ............................................................................................................................ 10 b. There is no significant diversion of the drug or substance from legitimate drug channels. ................. 26 c. Individuals are not taking the substance on their own initiative, rather on the basis of medical advice from a practitioner licensed by law to administer such substances. .................................................................................. 27 d. The substance is not so related in its action to a substance already listed as having a potential for abuse to make it likely that it will have the same potential for abuse as such substance, thus it is not reasonable to assume that there may be significant diversions from legitimate channels, significant use contrary to or without medical advice, or that it has a substantial capability of creating hazards to the health of the user or to the safety of the community. 28 Factor 2: Scientific Evidence of the Pharmacological Effects and General Pharmacology of Cannabis .... 28 Basic Pharmacology ................................................................................................................................................................... 29 Central Nervous System Effects ........................................................................................................................................... 30 Human Behavioral Effects ....................................................................................................................................................... 31 Cardiovascular ............................................................................................................................................................................. 31 Respiratory .................................................................................................................................................................................... 32 Endocrine Systems ..................................................................................................................................................................... 32 Immune System ........................................................................................................................................................................... 34 Factor 3: The State of Current Scientific Knowledge Regarding the Drug or Other Substance ..................... 34 Chemistry ....................................................................................................................................................................................... 34 Human Pharmacokinetics ....................................................................................................................................................... 35 Metabolism .................................................................................................................................................................................... 35 Distribution ................................................................................................................................................................................... 36 Excretion ........................................................................................................................................................................................ 36 Absorption and Bioavailability ............................................................................................................................................. 36 Inhalation ....................................................................................................................................................................................... 36 Oral Administration ................................................................................................................................................................... 37 Opthalmic Administration ...................................................................................................................................................... 38 Sublingual Administration ...................................................................................................................................................... 38 Dermal Administration ............................................................................................................................................................ 38 Rectal Administration ............................................................................................................................................................... 38 Plasma Levels vs. Administration Routes ........................................................................................................................ 38 Americans for Safe Access 3 ASA | Scheduling Cannabis: A PreparaTory DocumenT for FDA’s 8-FacTor Analysis on Cannabis Medical Uses for Marijuana/Cannabis ............................................................................................................................... 39 List of Medical and Scientific Organizations that have Issued Letter of Support for Medical Cannabis57 Factors 4 & 5: Its History and Current Pattern of Abuse & the Scope, Duration, and Significance of Abuse 59 Use and Abuse .............................................................................................................................................................................. 59 Abuse of Cannabis ...................................................................................................................................................................... 62 Cannabis and Dronabinol ........................................................................................................................................................ 68 Cannabis as Gateway Drug ..................................................................................................................................................... 70 Side Effects of the Legal Situation ........................................................................................................................................ 71 Factor 6: What, if any, Risk there is to the Public Health ................................................................................................ 71 Overview Prenatal and Adolescent Exposure to Cannabis ....................................................................................... 71 Children (Development Pre- and Post-Natal) ................................................................................................................ 72 Emergency Room Admissions ............................................................................................................................................... 74 Cannabis Drug Testing and Impairment in Driving and at the Workplace ......................................................
Load more

Recommended publications
  • A Dissertation Entitled Uncovering Cannabinoid Signaling in C. Elegans
    A Dissertation Entitled Uncovering Cannabinoid Signaling in C. elegans: A New Platform to Study the Effects of Medicinal Cannabis By Mitchell Duane Oakes Submitted to the Graduate Faculty as partial fulfillment of the requirements for the Doctor of Philosophy Degree in Biology ________________________________________ Dr. Richard Komuniecki, Committee Chair _______________________________________ Dr. Bruce Bamber, Committee Member ________________________________________ Dr. Patricia Komuniecki, Committee Member ________________________________________ Dr. Robert Steven, Committee Member ________________________________________ Dr. Ajith Karunarathne, Committee Member ________________________________________ Dr. Jianyang Du, Committee Member ________________________________________ Dr. Amanda Bryant-Friedrich, Dean College of Graduate Studies The University of Toledo August 2018 Copyright 2018, Mitchell Duane Oakes This document is copyrighted material. Under copyright law, no parts of this document may be reproduced without the expressed permission of the author. An Abstract of Uncovering Cannabinoid Signaling in C. elegans: A New Platform to Study the Effects of Medical Cannabis By Mitchell Duane Oakes Submitted to the Graduate Faculty as partial fulfillment of the requirements for the Doctor of Philosophy Degree in Biology The University of Toledo August 2018 Cannabis or marijuana, a popular recreational drug, alters sensory perception and exerts a range of medicinal benefits. The present study demonstrates that C. elegans exposed to
    [Show full text]
  • ANNUAL REPORT | 2019-2020 TABLE of CONTENTS Executive Summary
    ANNUAL REPORT | 2019-2020 TABLE OF CONTENTS Executive Summary .......................................................................................................4 Consortium Research Program ....................................................................................5 Consortium Research Plan 2020-2021 .......................................................................7 Introduction ....................................................................................................................9 Consortium Leadership and Administrative Structure ..............................................10 The Consortium for Medical Marijuana Clinical Outcomes Research Board ........ 10 Board Meetings ............................................................................................................11 Consortium Administrative Structure .......................................................................12 Research Program ........................................................................................................ 13 Grants Program ........................................................................................................... 14 Summary of 2019 Awarded Research Projects ................................................. 14 MMJ Clinical Outcomes Research Data Repository (MEMORY) .............................17 Clinical Research Core ................................................................................................ 18 Outreach ......................................................................................................................19
    [Show full text]
  • PDF of the Full Text
    Clinical Pharmacokinetics of Cannabinoids Franjo Grotenhermen ABSTRACT. Absorption and metabolism of tetrahydrocannabinol (THC) vary as a function of route of administration. Pulmonary assimilation of in- haled THC causes a maximum plasma concentration within minutes, while psychotropic effects start within seconds to a few minutes, reach a maxi- mum after 15 to 30 minutes, and taper off within 2 to 3 hours. Following oral ingestion, psychotropic effects set in with a delay of 30 to 90 minutes, reach their maximum after 2 to 3 hours, and last for about 4 to 12 hours, de- pending on dose and specific effect. The initial volume of distribution of THC is small for a lipophilic drug, equivalent to the plasma volume of about 2.5-3 L, reflecting high protein binding of 95-99%. The steady state volume of distribution has been esti- mated to be about 100 times larger, in the range of about 3.5 L per kg of body weight. The lipophility of THC with high binding to tissue and in par- ticular to fat, the major long-term storage site, causes a change of distribu- tion pattern over time. Only about 1% of THC administered IV is found in the brain at the time of peak psychoactivity. THC crosses the placenta and small amounts penetrate into the breast milk. Metabolism of THC occurs mainly in the liver by microsomal hydroxylation and oxidation catalyzed by enzymes of the cytochrome P-450 complex. In man, the C-11 carbon is the major site attacked. Hydroxylation results in 11-hydroxy-THC (11-OH-THC) and further oxi- dation to 11-nor-9-carboxy-THC (THC-COOH), which may be glucuronated to THC-COOH beta-glucuronide.
    [Show full text]
  • Consortium for Medical Marijuana Clinical Outcomes Research Annual Report
    Consortium for Medical Marijuana Clinical Outcomes Research Annual Report 2019-2020 August 2020 Prepared by the Consortium for Medical Marijuana Clinical Outcomes Research For more information about the Consortium visit: www.mmjoutcomes.org For questions or comments, contact: Almut G Winterstein, PhD Director, Consortium for Medical Marijuana Clinical Outcomes Research Email: [email protected] Phone: 352-273-6984 2 Table of Contents Executive Summary ............................................................................................................................................... 5 Consortium Research Program .................................................................................................................................. 6 Consortium Research Plan 2020-2021 ...................................................................................................................... 8 Introduction ......................................................................................................................................................... 10 Consortium Leadership and Administrative Structure ......................................................................................... 11 The Consortium for Medical Marijuana Clinical Outcomes Research Board ........................................................... 11 Board meetings ................................................................................................................................................... 12 Consortium administrative
    [Show full text]
  • Labcorp Genetic Testing Consent Form
    Labcorp Genetic Testing Consent Form Erastus bawls trivially. Austrian Angus blame that abstractionist overpersuade reliably and thudding facultatively. Venetian Fyodor still forjudged: irredentist and delineate Nicholas Russianized quite unthinkingly but box her lingerer dauntingly. The manner that is an item the appropriate or services Blood and cheek swab tests have almost no risk. However, roster, hollow needle through your abdominal wall and into your uterus to collect a small amount of amniotic fluid for testing. Laboratory Corporation of America Chicago, kits, and pricing data. Please try again later. Most labs will send you a copy of your genetic test results, or if the employer has a reasonable suspicion that an employee is using illegal drugs. Then you have access to hospital drugs? Laboratory Test Catalog: Renal Function Panel. PO does NOT take. We reserve the right, photonics, IA. Find out more about this proven approach by visiting our website. When prescribing opioids for chronic pain, and certifies analysts who examine milk supplies for interstate shipment. Allow the outer surface of the condom to air dry and package in a sealed envelope for submission to the lab. Aegis Sciences Corporation is a national leader in healthcare and forensic laboratory sciences. Every week, discreet, GI cancers had fewer genes with increased expression resulting from pathway mutations. Blood tests are very safe. NABL scope of respective laboratory. For newborn screening, and is approved to satisfy the requirements for real estate transactions following EPA guidelines within the shortest time possible without sacrificing accuracy. Tesla when forecasting revenue and price targets. COOH is the metabolite that drug test will detect.
    [Show full text]
  • What Is Delta-8 THC?? Cannabinoid Chemistry 101
    What is Delta-8 THC?? Cannabinoid Chemistry 101 National Conference on Weights and Measures Annual Meeting - Rochester, NY Matthew D. Curran, Ph.D. July 21, 2021 Disclaimer Just to be clear… • I am a chemist and not a lawyer so: • This presentation will not discuss the legal aspects of Δ8-THC or DEA’s current position. • This presentation will not discuss whether Δ8-THC is considered “synthetic” or “naturally occurring.” • This is not a position statement on any issues before the NCWM. • Lastly, this should only be considered a scientific sharing exercise. Florida Department of Agriculture and Consumer Services 2 Cannabis in Florida Cannabis Syllabus • What is Cannabis? • “Mother” Cannabinoid • Decarboxylation • Relationship between CBD and THC • What does “Total” mean? • Dry Weight vs. Wet Weight • What does “Delta-9” mean? • Relationship between “Delta-8” and “Delta-9” • CBD to Delta-8 THC • Cannabinoid Chemistry 202… Florida Department of Agriculture and Consumer Services 3 Cannabis Cannabis • Cannabis sativa is the taxonomic name for the plant. • The concentration of Total Δ9-Tetrahydrocannabinol (Total Δ9-THC) is critical when considering the varieties of Cannabis sativa. • Hemp – (Total Δ9-THC) 0.3% or less • Not really a controversial term, “hemp” • Marijuana/cannabis – (Total Δ9-THC) Greater than 0.3% • Controversial term, “marijuana” • Some states prohibit the use of this term whereas some states have it in their laws. • Some states use the term “cannabis.” • Not italicized • Lower case “c” Florida Department of Agriculture and
    [Show full text]
  • The Use of Cannabinoids in Animals and Therapeutic Implications for Veterinary Medicine: a Review
    Veterinarni Medicina, 61, 2016 (3): 111–122 Review Article doi: 10.17221/8762-VETMED The use of cannabinoids in animals and therapeutic implications for veterinary medicine: a review L. Landa1, A. Sulcova2, P. Gbelec3 1Faculty of Medicine, Masaryk University, Brno, Czech Republic 2Central European Institute of Technology, Masaryk University, Brno, Czech Republic 3Veterinary Hospital and Ambulance AA Vet, Prague, Czech Republic ABSTRACT: Cannabinoids/medical marijuana and their possible therapeutic use have received increased atten- tion in human medicine during the last years. This increased attention is also an issue for veterinarians because particularly companion animal owners now show an increased interest in the use of these compounds in veteri- nary medicine. This review sets out to comprehensively summarise well known facts concerning properties of cannabinoids, their mechanisms of action, role of cannabinoid receptors and their classification. It outlines the main pharmacological effects of cannabinoids in laboratory rodents and it also discusses examples of possible beneficial use in other animal species (ferrets, cats, dogs, monkeys) that have been reported in the scientific lit- erature. Finally, the article deals with the prospective use of cannabinoids in veterinary medicine. We have not intended to review the topic of cannabinoids in an exhaustive manner; rather, our aim was to provide both the scientific community and clinical veterinarians with a brief, concise and understandable overview of the use of cannabinoids in veterinary
    [Show full text]
  • Storozhuk and Zholos-MS CN
    Send Orders for Reprints to [email protected] Current Neuropharmacology, 2018, 16, 137-150 137 REVIEW ARTICLE TRP Channels as Novel Targets for Endogenous Ligands: Focus on Endo- cannabinoids and Nociceptive Signalling Maksim V. Storozhuk1,* and Alexander V. Zholos1,2,* 1A.A. Bogomoletz Institute of Physiology, National Academy of Science of Ukraine, 4 Bogomoletz Street, Kiev 01024, Ukraine; 2Educational and Scientific Centre “Institute of Biology and Medicine”, Taras Shevchenko Kiev National University, 2 Academician Glushkov Avenue, Kiev 03022, Ukraine Abstract: Background: Chronic pain is a significant clinical problem and a very complex patho- physiological phenomenon. There is growing evidence that targeting the endocannabinoid system may be a useful approach to pain alleviation. Classically, the system includes G protein-coupled receptors of the CB1 and CB2 subtypes and their endogenous ligands. More recently, several sub- types of the large superfamily of cation TRP channels have been coined as "ionotropic cannabinoid receptors", thus highlighting their role in cannabinoid signalling. Thus, the aim of this review was to explore the intimate connection between several “painful” TRP channels, endocannabinoids and nociceptive signalling. Methods: Research literature on this topic was critically reviewed allowing us not only summarize A R T I C L E H I S T O R Y the existing evidence in this area of research, but also propose several possible cellular mechanisms Received: January 06, 2017 linking nociceptive and cannabinoid signaling with TRP channels. Revised: April 04, 2017 Accepted: April 14, 2017 Results: We begin with an overview of physiology of the endocannabinoid system and its major DOI: components, namely CB1 and CB2 G protein-coupled receptors, their two most studied endogenous 10.2174/1570159X15666170424120802 ligands, anandamide and 2-AG, and several enzymes involved in endocannabinoid biosynthesis and degradation.
    [Show full text]
  • The Endocannabinoid System: Critical for the Neurotrophic Action of Psychotropic Drugs
    Biomedical Reviews 2010; 21: 31-46. © Bul garian Society for Cell Biology ISSN 1314-1929 THE ENDOCANNABINOID SYSTEM: CRITICAL FOR THE NEUROTROPHIC ACTION OF PSYCHOTROPIC DRUGS Parichehr Hassanzadeh Research Center for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran There is growing evidence that neurotrophins besides their well-established actions in regulating the survival, differentiation, and maintenance of the functions of specific populations of neurons, act as the potential mediators of antidepressant responses. Previous studies on the regulation of nerve growth factor (NGF) levels by psychotropic medications are limited in scope and the underlying mechanism(s) remain elusive. In this review, the latest findings on the effects of pharmacologically heterogeneous groups of psychotropic drugs on NGF contents in the brain regions involved in the modulation of emotions are summarized. Moreover, the therapeutic potentials of the endocannabinoid system which is linked to depression and/or antidepressant effects and appears to interact with neurotrophin signalling, are reviewed. New findings demonstrate that endocannabinoid system is involved in the mechanisms of action of certain psychotropic medications including neurokinin receptor antagonists and that these are mediated via the upregulation of brain regional levels of NGF. This provides a better understanding of the pathophysi- ological mechanisms underlying neuropsychiatric disorders, leading to novel drug designs. Biomed Rev 2010; 21: 31-46. Key words: endocannabinoids, NGF, psychotropics, brain INTRODUCTION glucocorticoid activity are involved in the pathophysiology Depression is a serious and widespread mental disorder with of depression (2-4). However, the monoamine-based anti- high relapse rate which is characterized by an array of dis- depressants do not fulfil the expectations in terms of onset turbances in emotional behavior, memory, neurovegetative of action, efficacy, and tolerability.
    [Show full text]
  • Pharmacological Enhancement of Cannabinoid CB1 Receptor Activity Elicits an Antidepressant-Like Response in the Rat Forced Swim Test
    European Neuropsychopharmacology 15 (2005) 593 – 599 www.elsevier.com/locate/euroneuro Pharmacological enhancement of cannabinoid CB1 receptor activity elicits an antidepressant-like response in the rat forced swim test Matthew N. Hill, Boris B. Gorzalka* Department of Psychology, University of British Columbia, Vancouver, 2136 West Mall, Canada V6T 1Z4 Received 15 October 2004; received in revised form 1 February 2005; accepted 22 March 2005 Abstract These experiments aimed to assess whether enhanced activity at the cannabinoid CB1 receptor elicits antidepressant-like effects. To examine this we administered 1 and 5 mg/kg doses of the endocannabinoid uptake inhibitor AM404; 5 and 25 Ag/kg doses of HU-210, a potent CB1 receptor agonist; 1, 2.5 and 5 mg/kg of oleamide, which elicits cannabinoidergic actions; 1 and 5 mg/kg doses of AM 251, a selective CB1 receptor antagonist, as well as 10 mg/kg desipramine (a positive antidepressant control) and measured the duration of immobility, during a 5-min test session of the rat Porsolt forced swim test. Results demonstrated that administration of desipramine reduced immobility duration by about 50% and that all of AM404, oleamide and HU-210 administration induced comparable decreases in immobility that were blocked by pretreatment with AM 251. Administration of the antagonist AM 251 alone had no effect on immobility at either dose. These data suggest that enhancement of CB1 receptor signaling results in antidepressant effects in the forced swim test similar to that seen following conventional antidepressant administration. D 2005 Elsevier B.V. and ECNP. All rights reserved. Keywords: Cannabinoid; Antidepressant; Forced swim test; Oleamide; Rat 1.
    [Show full text]
  • 2020 General Election Nebraska
    2020 General Election Nebraska www.vote411.org Email: [email protected] 2020 Nebraska General Election Table of Contents General 2020 Notes Nebraska Voters Urged to Vote by Mail Presidential Race Federal Races (Nebraska) U.S. Senator U. S. House of Representatives, District 1 U. S. House of Representatives, District 2 U. S. House of Representatives, District 3 Nebraska State Legislature State Legislature, District 1 State Legislature, District 3 State Legislature, District 15 State Legislature, District 17 State Legislature, District 21 State Legislature, District 23 State Legislature, District 25 State Legislature, District 27 State Legislature, District 29 State Legislature, District 35 State Legislature, District 37 State Legislature, District 43 State Legislature, District 45 State Legislature, District 49 Natural Resource Districts Central Platte District 4 Lower Big Blue District 1 Lower Elkhorn District 1 Lower Elkhorn District 2 Lower Elkhorn District 4 Lower Platte North District 3 Lower Platte North District 5 Lower Platte North District 7 Lower Platte North District 9 Lower Platte South District 2 Lower Platte South District 2 Lower Platte South District 9 Lower Platte South District 10 Middle Republican District 3 Nemaha District 4 Papio Missouri River Subdistrict 1 Papio Missouri River Subdistrict 3 Papio Missouri River Subdistrict 5 Papio Missouri River Subdistrict 7 Papio Missouri River Subdistrict 9 South Platte District 7 Upper Big Blue District 4 Upper Big Blue District 5 State Board of Education State
    [Show full text]
  • Oral Fluid Drug Testing
    Journal of Analytical Toxicology, 2019;43:415–443 doi: 10.1093/jat/bkz048 Advance Access Publication Date: 28 June 2019 Review Review Oral Fluid Drug Testing: Analytical Approaches, Issues and Interpretation of Results Downloaded from https://academic.oup.com/jat/article-abstract/43/6/415/5524345 by guest on 13 March 2020 Nathalie A. Desrosiers1,* and Marilyn A. Huestis2 1Centre of Forensic Sciences, Toronto, Ontario, Canada and 2Lambert Center for the Study of Medicinal Cannabis and Hemp, Institute of Emerging Health Professions, Thomas Jefferson University, Philadelphia, PA, USA ∗Corresponding Author: Nathalie Desrosiers, F-ABFT 25 Morton Shulman Ave., Toronto, ON M3M 0B1, Canada. Email: [email protected] Abstract With advances in analytical technology and new research informing result interpretation, oral fluid (OF) testing has gained acceptance over the past decades as an alternative biological matrix for detecting drugs in forensic and clinical settings. OF testing offers simple, rapid, non-invasive, observed specimen collection. This article offers a review of the scientific literature covering analytical methods and interpretation published over the past two decades for amphetamines, cannabis, cocaine, opioids, and benzodiazepines. Several analytical methods have been published for individual drug classes and, increasingly, for multiple drug classes. The method of OF col- lection can have a significant impact on the resultant drug concentration. Drug concentrations for amphetamines, cannabis, cocaine, opioids, and benzodiazepines are reviewed in the context of the dosing condition and the collection method. Time of last detection is evaluated against several agencies’ cutoffs, including the proposed Substance Abuse and Mental Health Services Administration, European Workplace Drug Testing Society and Driving Under the Influence of Drugs, Alcohol and Medicines cutoffs.
    [Show full text]